Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Warning Letters
Manufacturing
Aurobindo discloses FDA Form 483 at North Carolina inhaler plant
Aurobindo's Aurolife Pharma received an FDA Form 483 outlining 11 observations at a North Carolina plant, the Indian drugmaker said late last week.
Joseph Keenan
Apr 14, 2025 3:00pm
Aspen Pharmacare hit with warning letter citing sterility issues
Mar 20, 2025 9:45am
FDA hits 2 Indian API makers with warning letters, import alerts
Feb 20, 2025 9:05am
Viatris says India plant hit with FDA warning letter, import ban
Dec 23, 2024 10:50am
FDA slams Indian drugmaker Unexo with warning letter
Nov 20, 2024 9:25am
FDA scrutinizes Novo on production issues at semaglutide plant
Oct 31, 2024 9:33am